Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma-Reference-Cited by-同舟云学术

Integrated analysis of multiple receptor tyrosine kinases identifies Axl as a therapeutic target and mediator of resistance to sorafenib in hepatocellular carcinoma

Published:2019-02-15 Issue:5 Volume:120 Page:512-521
ISSN:0007-0920
Container-title:British Journal of Cancer
language:en
Short-container-title:Br J Cancer

Author:

Pinato David J.,Brown Matthew W.,Trousil Sebastian,Aboagye Eric O.,Beaumont Jamie,Zhang Hua,Coley Helen M.,Mauri Francesco A.,Sharma Rohini

Funder

Academy of Medical Sciences

DeAgostini Foundation, Action Against Cancer.

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Oncology

Link

http://www.nature.com/articles/s41416-018-0373-6.pdf

Reference57 articles.

1. Tabrizian, P., Roayaie, S. & Schwartz, M. E. Current management of hepatocellular carcinoma. World J. Gastroenterol. 20, 10223–10237 (2014).

2. Pinato, D. J., Howell, J., Ramaswami, R. & Sharma, R. Review article: delivering precision oncology in intermediate-stage liver cancer. Aliment. Pharmacol. Ther. 45, 1514–1523 (2017).

3. Forner, A., Gilabert, M., Bruix, J. & Raoul, J. L. Treatment of intermediate-stage hepatocellular carcinoma. Nat. Rev. Clin. Oncol. 11, 525–535 (2014).

4. Jackson, R., Psarelli, E. E., Berhane, S., Khan, H. & Johnson, P. Impact of viral status on survival in patients receiving sorafenib for advanced hepatocellular cancer: a meta-analysis of randomized phase III trials. J. Clin. Oncol. 35, 622–628 (2017).

5. Llovet, J. M. et al. Sorafenib in advanced hepatocellular carcinoma. N. Engl. J. Med. 359, 378–390 (2008).

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Regulation of lung cancer initiation and progression by the stem cell determinant Musashi;2024-09-12

2. Regulation of lung cancer initiation and progression by the stem cell determinant Musashi;2024-09-12

3. Targeting AXL induces tumor-intrinsic immunogenic response in tyrosine kinase inhibitor-resistant liver cancer;Cell Death & Disease;2024-02-03

4. GAS6/TAM Axis as Therapeutic Target in Liver Diseases;Seminars in Liver Disease;2024-02

5. From MASH to HCC: the role of Gas6/TAM receptors;Frontiers in Immunology;2024-01-17